Analysts Set Expectations for Regulus Therapeutics Inc’s FY2022 Earnings (NASDAQ:RGLS)

Regulus Therapeutics Inc (NASDAQ:RGLS) – Equities researchers at Wedbush issued their FY2022 EPS estimates for shares of Regulus Therapeutics in a note issued to investors on Thursday, according to Zacks Investment Research. Wedbush analyst L. Moussatos expects that the biopharmaceutical company will post earnings of $0.47 per share for the year. Wedbush has a “Outperform” rating and a $4.00 price target on the stock.

Other analysts have also issued reports about the stock. Zacks Investment Research raised shares of Regulus Therapeutics from a “hold” rating to a “buy” rating and set a $1.50 price target for the company in a research note on Wednesday, January 24th. Needham & Company LLC reissued a “hold” rating on shares of Regulus Therapeutics in a research note on Tuesday, November 14th. Chardan Capital reissued a “neutral” rating on shares of Regulus Therapeutics in a research note on Tuesday, January 16th. Finally, Leerink Swann initiated coverage on shares of Regulus Therapeutics in a research note on Friday, January 5th. They set an “outperform” rating and a $2.00 target price for the company. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and three have issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average target price of $2.50.

Shares of Regulus Therapeutics (NASDAQ:RGLS) traded down $0.02 during trading hours on Monday, hitting $1.20. 503,100 shares of the stock were exchanged, compared to its average volume of 564,792. The firm has a market cap of $124.75, a price-to-earnings ratio of -0.89 and a beta of 1.72. Regulus Therapeutics has a 12 month low of $0.79 and a 12 month high of $1.95. The company has a current ratio of 6.77, a quick ratio of 6.77 and a debt-to-equity ratio of 0.41.

Institutional investors have recently added to or reduced their stakes in the business. NEA Management Company LLC acquired a new position in Regulus Therapeutics in the 3rd quarter valued at approximately $13,737,000. Victory Capital Management Inc. bought a new stake in Regulus Therapeutics in the third quarter worth approximately $347,000. Goldman Sachs Group Inc. grew its position in Regulus Therapeutics by 189.1% in the second quarter. Goldman Sachs Group Inc. now owns 368,285 shares of the biopharmaceutical company’s stock worth $363,000 after acquiring an additional 240,890 shares in the last quarter. Candriam Luxembourg S.C.A. bought a new stake in Regulus Therapeutics in the third quarter worth approximately $750,000. Finally, South Dakota Investment Council grew its position in Regulus Therapeutics by 37.1% in the third quarter. South Dakota Investment Council now owns 1,820,027 shares of the biopharmaceutical company’s stock worth $2,275,000 after acquiring an additional 492,969 shares in the last quarter. Hedge funds and other institutional investors own 57.83% of the company’s stock.

WARNING: “Analysts Set Expectations for Regulus Therapeutics Inc’s FY2022 Earnings (NASDAQ:RGLS)” was reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this article on another publication, it was illegally stolen and republished in violation of US & international trademark and copyright law. The correct version of this article can be viewed at https://ledgergazette.com/2018/02/20/regulus-therapeutics-inc-forecasted-to-post-fy2022-earnings-of-0-47-per-share-rgls.html.

Regulus Therapeutics Company Profile

Regulus Therapeutics Inc is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state.

Get a free copy of the Zacks research report on Regulus Therapeutics (RGLS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Regulus Therapeutics (NASDAQ:RGLS)

Receive News & Ratings for Regulus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply